Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Authors Omar S Din, Penella J Woll

Published 8 February 2008 Volume 2008:4(1) Pages 149—162

DOI https://doi.org/10.2147/TCRM.S1526

Omar S Din, Penella J Woll

Academic Department of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield, UK

Abstract: Gastrointestinal stromal tumor (GIST) is a rare primary neoplasm of the gastrointestinal tract, mesentery, or omentum. In the past, surgery has been the only effective treatment. The diagnosis and treatment of GIST has been revolutionized over the past decade, since expression of the receptor tyrosine kinase KIT was shown to occur on these tumors. Mutations in this proto-oncogene commonly cause constitutive activation of the KIT tyrosine kinase receptor, an important factor in the pathogenesis of the disease. The development of specific tyrosine kinase inhibitors, such as imatinib mesylate, has led to a breakthrough in the treatment of advanced GIST. Treatment with this drug has led to significant improvements in survival, with overall response rates in excess of 80%. Side effects are common, but usually manageable. The success of this drug has led to further trials investigating its use in the pre- and postoperative situation. This review summarizes the current knowledge of GIST and imatinib treatment and possible future developments.

Keywords: imatinib, STI-571, GIST, gastrointestinal, stromal, tumor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Mohammad Fayyaz, Jeffrey M Lackner

Therapeutics and Clinical Risk Management 2008, 4:41-48

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

Martin Henkes, Heiko van der Kuip, Walter E Aulitzky

Therapeutics and Clinical Risk Management 2008, 4:163-187

Published Date: 8 February 2008

Zoledronic acid in the management of metastatic bone disease

Thomas J Polascik, Vladimir Mouraviev

Therapeutics and Clinical Risk Management 2008, 4:261-268

Published Date: 8 February 2008

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results

Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Carlo Lombardi, et al

Therapeutics and Clinical Risk Management 2007, 3:569-578

Published Date: 15 September 2007

Detection and remediation of medically urgent situations using telemedicine case management for older patients with diabetes mellitus

Roberto Izquierdo, Suzanne Meyer, Justin Starren, Robin Goland, Jeanne Teresi, et al

Therapeutics and Clinical Risk Management 2007, 3:485-489

Published Date: 15 July 2007